title: Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.
abstract: Prior to a chimpanzee adenovirus-based (ChAd63) malarial vaccine trial, sera were collected to assess ChAd63-specific neutralizing antibody titers in Banfora (Burkina Faso). The low neutralizing antibody titers reported in both adults and children (median titers, 139.1 and 35.0, respectively) are encouraging for the potential use of ChAd63 as a malarial vaccine vector.
authors.affiliation: Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso issanebie.cnlp@fasonet.bf.
authors.forename: Issa
authors.initials: I
authors.lastname: Nébié
authors.affiliation: Centre for Clinical Vaccinology and Tropical Medicine and the Jenner Institute Laboratories, University of Oxford, Oxford, United Kingdom.
authors.forename: Nick J
authors.initials: NJ
authors.lastname: Edwards
authors.affiliation: Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
authors.forename: Alfred B
authors.initials: AB
authors.lastname: Tiono
authors.affiliation: Centre for Clinical Vaccinology and Tropical Medicine and the Jenner Institute Laboratories, University of Oxford, Oxford, United Kingdom.
authors.forename: Katie J
authors.initials: KJ
authors.lastname: Ewer
authors.affiliation: Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
authors.forename: Guillaume S
authors.initials: GS
authors.lastname: Sanou
authors.affiliation: Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
authors.forename: Issiaka
authors.initials: I
authors.lastname: Soulama
authors.affiliation: Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
authors.forename: Souleymane
authors.initials: S
authors.lastname: Sanon
authors.affiliation: Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
authors.forename: Amidou
authors.initials: A
authors.lastname: Diarra
authors.affiliation: Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
authors.forename: Jean Baptiste
authors.initials: JB
authors.lastname: Yaro
authors.affiliation: Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
authors.forename: David
authors.initials: D
authors.lastname: Kangoye
authors.affiliation: European Vaccine Initiative, Heidelberg, Germany.
authors.forename: Egeruan B
authors.initials: EB
authors.lastname: Imoukhuede
authors.affiliation: Centre for Clinical Vaccinology and Tropical Medicine and the Jenner Institute Laboratories, University of Oxford, Oxford, United Kingdom.
authors.forename: Adrian V S
authors.initials: AV
authors.lastname: Hill
authors.affiliation: Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
authors.forename: Sodiomon B
authors.initials: SB
authors.lastname: Sirima
mesh_terms: D000261:Adenoviruses, Simian / Q000145:classification / Q000276:immunology*; D000293:Adolescent; D000328:Adult; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood* / Q000276:immunology; D000914:Antibodies, Viral / Q000097:blood* / Q000276:immunology; D002050:Burkina Faso; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D006801:Humans; D007223:Infant; D017780:Malaria Vaccines / Q000276:immunology*; D016778:Malaria, Falciparum / Q000276:immunology* / Q000517:prevention & control; D008875:Middle Aged; D002679:Pan troglodytes; D055815:Young Adult
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D017780:Malaria Vaccines
references.citation: Sci Transl Med. 2012 Jan 4;4(115):115ra1
references.pmid: 22218690
references.citation: Gene Ther. 2006 Mar;13(5):421-9
references.pmid: 16319951
references.citation: Neurol Res. 2003 Mar;25(2):130-42
references.pmid: 12635511
references.citation: Sci Transl Med. 2012 Jan 4;4(115):115ra2
references.pmid: 22218691
references.citation: J Gen Virol. 2006 Sep;87(Pt 9):2477-2485
references.pmid: 16894185
references.citation: J Clin Microbiol. 2006 Oct;44(10):3781-3
references.pmid: 17021110
references.citation: Eur J Immunol. 2008 Mar;38(3):732-41
references.pmid: 18266272
references.citation: J Virol. 1996 Nov;70(11):7498-509
references.pmid: 8892868
references.citation: J Infect Dis. 2012 Mar 1;205(5):772-81
references.pmid: 22275401
references.citation: Virology. 2010 Nov 10;407(1):1-6
references.pmid: 20797754
references.citation: Nat Commun. 2013;4:2836
references.pmid: 24284865
references.citation: Vaccine. 2009 Jun 2;27(27):3501-4
references.pmid: 19464527
references.citation: Mol Ther. 2011 Dec;19(12):2269-76
references.pmid: 21862998
references.citation: J Virol. 2003 Oct;77(19):10366-75
references.pmid: 12970421
references.citation: Hum Gene Ther. 2004 Mar;15(3):293-304
references.pmid: 15018738
references.citation: J Immunol. 2003 Dec 15;171(12):6774-9
references.pmid: 14662882
references.citation: PLoS One. 2012;7(7):e40385
references.pmid: 22808149
references.citation: J Virol. 1988 Jul;62(7):2321-8
references.pmid: 3373570
references.citation: J Gen Virol. 2006 Oct;87(Pt 10):2891-2899
references.pmid: 16963747